At this premier scientific meeting, the world's leading researchers gather to present data and discuss recent directions in oncology research, with a focus on translating the most recent laboratory developments into the development of treatments that improve clinical outcomes for cancer patients. The program, developed under the direction of co-chairs Dennis J. Slamon, MD, PhD, and John Crown, MD, MPH, includes relevant didactic presentations and compelling, interactive discussions.
Faculty are carefully selected from among the researchers at the forefront of the translational work in the topic, whether from academia, government, or industry. The program encourages networking and interaction between the attendees and the renowned faculty members.
Agenda
Thursday, October 16
12:00 PM - 6:00 PM Registration
6:30 PM - 9:30 PM Welcome Reception
Friday, October 17
7:00 AM - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session I: Growth Factors and Growth Factor Receptors
Chair: Dennis J. Slamon, MD, PhD
UCLA David Geffen School of Medicine
The IGFR Signaling Pathway as a Novel Therapeutic Target
Renato Baserga, MD
Kimmel Cancer Center at Jefferson
IGF1 Pathway
Frank Calzone, PhD
Amgen
EGF Pathway
Bruce Johnson, MD
Dana Farber Cancer Institute
Pan-HER Inhibitors in Patients With Advanced Cancer
Ian Taylor, PhD
Pfizer
Highly Selective Small Molecule Inhibitors of c-MET and Their Role in Human Cancers
James Christensen, PhD
Pfizer
HDAC Inhibition in Breast Cancer
Ramona F. Swaby, MD
Fox Chase Cancer Center
10:00 AM - 10:30 AM Break
10:30 AM - 12:30 PM Session II: Steroid Hormonal Receptors and Their Manipulation
Chair: Brian Leyland-Jones, MD, PhD
Emory Winship Cancer Institute
Antitumor Activity of Abiraterone Acetate in Castration-Resistant Prostate Cancer
Timothy Yap, BSc (Hons), MB BS, MRCP
Royal Marsden Hospital
Pharmacogenetics of Endocrine Therapy
James M. Rae, PhD
University of Michigan
Impact of Altered Growth Factor Signaling on Estrogen Receptor Expression
Dorraya El-Ashry, PhD
University of Miami
TBD
Brian Leyland-Jones, MD PhD
Emory Winship Cancer Institute
12:30 PM - 2:00 PM Lunch
2:00 PM - 4:00 PM Session III: Apoptosis and Programmed Cell Death
Chair: Tak Mak, MD
Princess Margaret Hospital
The Perivascular Niche and Therapeutic Resistance
Eric Holland, MD
Memorial Sloan-Kettering Cancer Center
Bcl-2 Inhibition for the Treatment of Cancer
Gordon Shore, PhD
McGill Unversity
TRAIL Receptor Targeting
Wafik El-Deiry, MD, PhD
University of Pennsylvania
What Will be the Next Generation of Cancer Targets?
Tak Mak, MD
Princess Margaret Hospital
4:00 PM Afternoon Refreshments
Saturday, October 18
7:00 AM - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session IV: Malignant Angiogenesis and Antiangiogenic Therapies
Chair: George W. Sledge, Jr., MD
Indiana University
Angiopoietin/Tie2 Signaling in Tumor Angiogenesis
Charles Lin, PhD
Vanderbilt University
Pazopanib, a VEGF Inhibitor
Dennis J. Slamon, MD, PhD
UCLA David Geffen School of Medicine
Resistance to VEGF-Targeting Agents
Robert Kerbel, PhD
University of Toronto
Lessons Learned: Clinical Trials of Antiangiogenic Agents
George W. Sledge, Jr., MD
Indiana University
10:00 AM - 10:30 AM Break
10:30 AM - 12:30 PM Session V: Malignant Stem Cells as Targets in Oncology
Chair: Hasan Korkaya, DVM, PhD
University of Michigan
IL-4 Signaling in Colon Cancer Stem Cells
Giorgio Stassi, PhD
University of Palermo
PI3-K/Akt Pathway Role on Mammary Stem Cells
Hasan Korkaya, DVM, PhD
University of Michigan
Wnt/Beta-Catenin Signaling Pathway
Paul Polakis, PhD
Genentech
Targeting the Hedgehog Pathway in Cancer
Frederic J. de Sauvage, PhD
Genentech
12:30 - 1:30 PM Lunch
1:30 - 2:00 PM Translational Research: Have We Lost Sight of the Goal? A Patient's Perspective
Fran Visco, JD
National Breast Cancer Coalition Foundation
2:00 - 4:00 PM Session VI: Immunotherapies and Vaccine Strategies
Chair: John Glaspy, MD
UCLA Jonsson Comprehensive Cancer Center
Antibodies for Modulating Anti-Tumor Responses
John Glaspy, MD
UCLA Jonsson Comprehensive Cancer Center
Anti-CTLA4
Antoni Ribas, MD
UCLA Jonsson Comprehensive Cancer Center
Clinical Development of PD-1 Blockade in Cancer Therapy
Suzanne L. Topalian, MD
Sidney Kimmel Comprehensive Cancer Center
Adoptive T-Cell Transfer for Metastatic Melanoma
James Yang, MD
National Institutes of Health
4:00 PM Afternoon Refreshments
Sunday, October 19
7:00 - 8:00 AM Breakfast
8:00 AM - 10:00 AM Session VII: Signal Transduction: Targets in the Malignant Signaling Process
Chair: Neal Rosen, MD. PhD
Memorial Sloan-Kettering Cancer Center
Genetic Predictors of MEK-Dependence
David Solit, MD
Memorial Sloan-Kettering Cancer Center
mTOR Inhibitors as Cancer Chemotherapy Drugs
Jay Gibbons, Jr., PhD
Wyeth
Ras Pathway and Pancreatic Cancer
David Tuveson, PhD
Cancer Research UK Cambridge Research Institute
Akt Inhibition
Neal Rosen, MD, PhD
Memorial Sloan-Kettering Cancer Center
10:00 AM - 10:15 AM Break
10:15 AM - 12:15 PM Session VIII: Identification of Signaling Pathways and Genetic Markers in Cancer
Chair: Lajos Pusztai, MD, PhD
MD Anderson Cancer Center
Discovery of the Next Generation of Drug Targets From Human Gene Expression Data
Lajos Pusztai, MD, PhD
MD Anderson Cancer Center
Genomic Approaches to Understanding Cancer Biology and Treatment
Paul Spellman, PhD
University of California, Berkeley
PI3-K/mTOR Signaling as a Therapeutic Target for Breast Cancer
Funda Meric-Bernstam, MD
MD Anderson Cancer Center
Mechanisms of Resistance to ErbB2 Kinase Inhibitors
Neil Spector, MD
Duke University
Preclinical Models in Drug Development
Richard S. Finn, MD
UCLA David Geffen School of Medicine
12:15 PM - 12:30 PM Concluding Remarks
12:30 PM Box Lunch and Departures